SABCS15: Promising phase 1 results lead to phase 2 for ONT-380 in HER2+ breast cancer

(University of Colorado Anschutz Medical Campus) Results of an ongoing phase 1b clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show promise of the experimental anti-cancer agent ONT-380 against metastatic HER2+ breast cancer, especially against brain metastases commonly associated with progression of the disease.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news